Patents by Inventor William G. Hanson

William G. Hanson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10526609
    Abstract: The present invention provides nucleic acid and protein sequences that enhance the expression of fusion proteins by host cells, and in particular bacterial species, together with methods use thereof. While described hereinafter in terms of expression of fusion proteins by Listeria monocytogenes, the present invention is applicable to expression of fusion proteins generally.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 7, 2020
    Assignee: ADURO BIOTECH, INC.
    Inventors: Peter M. Lauer, William G. Hanson
  • Patent number: 10105427
    Abstract: Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to fusion proteins comprising an epidermal growth factor receptor variant III (EGFRvIII) polypeptide and a mesothelin polypeptide, and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins. In some embodiments, the nucleic acid molecules can encode an EGFRvIII-mesothelin fusion protein comprising an amino acid sequence that is at least i) 90% identical, ii) 95% identical, or iii) 99% identical to EGFRvIIIx5-mesothelin35-622 as set forth in SEQ ID NO:8.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: October 23, 2018
    Assignee: ADURO BIOTECH, INC.
    Inventors: Peter M. Lauer, William G. Hanson
  • Publication number: 20180085446
    Abstract: Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to immunogenic fusion proteins and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins.
    Type: Application
    Filed: September 29, 2017
    Publication date: March 29, 2018
    Inventors: Dirk G. Brockstedt, Charles G. Drake, Marcella Fasso, Peter M. Lauer, William G. Hanson, Meredith Lai Ling Leong, Christopher Steven Rae
  • Publication number: 20180030457
    Abstract: The present invention provides nucleic acid and protein sequences that enhance the expression of fusion proteins by host cells, and in particular bacterial species, together with methods use thereof. While described hereinafter in terms of expression of fusion proteins by Listeria monocytogenes, the present invention is applicable to expression of fusion proteins generally.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 1, 2018
    Applicant: ADURO BIOTECH, INC.
    Inventors: Peter M. LAUER, William G. HANSON
  • Patent number: 9808516
    Abstract: Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to immunogenic fusion proteins and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: November 7, 2017
    Assignees: Aduro Biotech, Inc., The Johns Hopkins University
    Inventors: Dirk G. Brockstedt, Charles G. Drake, Marcella Fasso, Peter M. Lauer, William G. Hanson, Meredith Lai Ling Leong, Christopher Steven Rae
  • Publication number: 20170253637
    Abstract: The present invention provides nucleic acids, expression systems, and vaccine strains which provide efficient expression and secretion of antigens of interest into the cytosol of host cells, and elicit effective CD4 and CD8 T cell responses by functionally linking Listerial or other bacterial signal peptides/secretion chaperones as N-terminal fusion partners in translational reading frame with selected recombinant encoded protein antigens. These N-terminal fusion partners are deleted (either by actual deletion, by mutation, or by a combination of these approaches) for any PEST sequences native to the sequence, and/or for certain hydrophobic residues.
    Type: Application
    Filed: May 18, 2017
    Publication date: September 7, 2017
    Inventors: Peter M. Lauer, William G. Hanson, Justin Skoble, Meredith Lai Ling Leong, Marcella Fasso, Dirk Brockstedt, Thomas W. Dubensky, JR.
  • Patent number: 9663557
    Abstract: The present invention provides nucleic acids, expression systems, and vaccine strains which provide efficient expression and secretion of antigens of interest into the cytosol of host cells, and elicit effective CD4 and CD8 T cell responses by functionally linking Listerial or other bacterial signal peptides/secretion chaperones as N-terminal fusion partners in translational reading frame with selected recombinant encoded protein antigens. These N-terminal fusion partners are deleted (either by actual deletion, by mutation, or by a combination of these approaches) for any PEST sequences native to the sequence, and/or for certain hydrophobic residues.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: May 30, 2017
    Assignee: ADURO BIOTECH, INC.
    Inventors: Peter M. Lauer, William G. Hanson, Justin Skoble, Meredith Lai Ling Leong, Marcella Fasso, Dirk Brockstedt, Thomas W. Dubensky, Jr.
  • Publication number: 20170081673
    Abstract: The present invention provides facultatively attenuated bacterial species and methods of preparation and use thereof. The term “facultatively attenuated” as used herein refers to a bacterium which comprises a set of defined recombinant modifications which have substantially no effect on the ability of the bacterium to grow by multiplication when the bacterium is outside of its host organism, but which result in deletion of one or more genes essential for multiplication of the bacterium when the bacterium is introduced into its host organism, for example within host cells of a vaccinate recipient. These recombinant modifications take advantage of regulatory sequences which preferentially induce expression of genes within the mammalian host.
    Type: Application
    Filed: December 5, 2016
    Publication date: March 23, 2017
    Inventors: William G. HANSON, Justin SKOBLE, Peter M. LAUER
  • Patent number: 9511129
    Abstract: The present invention provides facultatively attenuated bacterial species and methods of preparation and use thereof. The term “facultatively attenuated” as used herein refers to a bacterium which comprises a set of defined recombinant modifications which have substantially no effect on the ability of the bacterium to grow by multiplication when the bacterium is outside of its host organism, but which result in deletion of one or more genes essential for multiplication of the bacterium when the bacterium is introduced into its host organism, for example within host cells of a vaccinate recipient. These recombinant modifications take advantage of regulatory sequences which preferentially induce expression of genes within the mammalian host.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: December 6, 2016
    Assignee: ADURO BIOTECH, INC.
    Inventors: William G. Hanson, Justin Skoble, Peter M. Lauer
  • Publication number: 20160346369
    Abstract: Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to fusion proteins comprising an epidermal growth factor receptor variant III (EGFRvIII) polypeptide and a mesothelin polypeptide, and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins. In some embodiments, the nucleic acid molecules can encode an EGFRvIII-mesothelin fusion protein comprising an amino acid sequence that is at least i) 90% identical, ii) 95% identical, or iii) 99% identical to EGFRvIII×5-mesothelin35-622 as set forth in SEQ ID NO:8.
    Type: Application
    Filed: April 12, 2016
    Publication date: December 1, 2016
    Inventors: Peter M. Lauer, William G. Hanson
  • Publication number: 20160324945
    Abstract: Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to immunogenic fusion proteins and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins.
    Type: Application
    Filed: April 12, 2016
    Publication date: November 10, 2016
    Inventors: Dirk G. Brockstedt, Charles G. Drake, Marcella Fasso, Peter M. Lauer, William G. Hanson, Meredith Lai Ling Leong, Christopher Steven Rae
  • Publication number: 20140186387
    Abstract: The present invention provides nucleic acids, expression systems, and vaccine strains which provide efficient expression and secretion of antigens of interest into the cytosol of host cells, and elicit effective CD4 and CD8 T cell responses by functionally linking Listerial or other bacterial signal peptides/secretion chaperones as N-terminal fusion partners in translational reading frame with selected recombinant encoded protein antigens. These N-terminal fusion partners are deleted (either by actual deletion, by mutation, or by a combination of these approaches) for any PEST sequences native to the sequence, and/or for certain hydrophobic residues.
    Type: Application
    Filed: December 27, 2013
    Publication date: July 3, 2014
    Applicant: ADURO BIOTECH, INC.
    Inventors: Peter M. Lauer, William G. Hanson, Justin Skoble, Meredith Lai Ling Leong, Marcella Fasso, Dirk Brockstedt, Thomas W. Dubensky, JR.
  • Publication number: 20140127816
    Abstract: The present invention provides facultatively attenuated bacterial species and methods of preparation and use thereof. The term “facultatively attenuated” as used herein refers to a bacterium which comprises a set of defined recombinant modifications which have substantially no effect on the ability of the bacterium to grow by multiplication when the bacterium is outside of its host organism, but which result in deletion of one or more genes essential for multiplication of the bacterium when the bacterium is introduced into its host organism, for example within host cells of a vaccinate recipient. These recombinant modifications take advantage of regulatory sequences which preferentially induce expression of genes within the mammalian host.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 8, 2014
    Applicant: ADURO BIOTECH
    Inventors: William G. HANSON, Justin SKOBLE, Peter M. LAUER
  • Publication number: 20100129406
    Abstract: The invention provides Listeria that, in addition to comprising polynucleotides that encode heterologous polypeptides such as tumor or infectious agent antigens, have been modified to express holin proteins that facilitate the delivery of the heterologous polypeptides, or polynucleotides encoding the same, outside of the bacteria. In some particular embodiments, the Listeria generate viral-derived, self-replicating RNAs that direct expression of the heterologous polypeptides in the cytosol of infected cells. Methods of using the Listeria, and compositions thereof, to induce immune response and/or in the prevention or treatment of disease are also provided. Methods of producing the bacteria are also provided.
    Type: Application
    Filed: August 31, 2007
    Publication date: May 27, 2010
    Applicant: ANZA THERAPEUTICS, INC.
    Inventors: Peter M. Lauer, Thomas W. Dubensky, JR., William S. Luckett, William G. Hanson
  • Patent number: 6521458
    Abstract: The present invention provides methods for eliminating plants containing non-T-DNA sequences derived from a T-DNA vector. More specifically, the present invention provides a method for killing plant cells that receive non-T-DNA sequences based on incorporation of a lethal polynucleotide sequence into the non-T-DNA portion of the vector.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: February 18, 2003
    Assignee: DNA Plant Technology Corporation
    Inventors: Neal Gutterson, William G. Hanson
  • Patent number: 5956463
    Abstract: The invention relates to an automated system for monitoring wildlife auditory data and recording same for subsequent analysis and identification. The system comprises one or more microphones coupled to a recording apparatus for recording wildlife vocalizations in digital format. The resultant recorded data is preprocessed, segmented, and analyzed by means of a neural network to identify the respective species. The system minimizes the need for human intervention and subjective interpretation of the recorded sounds.
    Type: Grant
    Filed: October 7, 1996
    Date of Patent: September 21, 1999
    Assignee: Ontario Hydro
    Inventors: Paul H. Patrick, Narayan Ramani, William G. Hanson, Ronald W. Sheehan, Robert L. Jennette